NEW YORK (GenomeWeb News) – Celsis In Vitro Technologies, a division of life science products and lab services firm Celsis International, today announced that it is collaborating with Promega on ADME-Tox assays for hepatocytes.

Baltimore-based Celsis IVT said that it will provide pre-qualified lots of its cryopreserved hepatocytes for use with Promega's bioluminescent ADME-Tox assays, including those used to study cytochrome P450 gene induction and inhibition and its GSH-Glo Glutathione assay for investigating mechanisms of hepatoxicity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.